8-K ·Filed Apr 22, 2026
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish
Monitor upcoming clinical trial results and potential partnerships, as positive data could increase the value of stenoparib's development program.
Final — all horizons settled through T+60d
ALLR ▼ -15.00% at T+60d
LONG call ✗ call lost -15.00% · α vs SPY -19.78% · entry $1.40 → $1.19
T+1d
0.00%
call 0.00% · α +0.39%
$1.40
settled 6mo ago
T+5d
-0.81%
call -0.81% · α -0.87%
$1.39
settled 6mo ago
T+20d
+6.43%
call +6.43% · α +3.26%
$1.49
settled 5mo ago
T+60d
-15.00%
call -15.00% · α -19.78%
$1.19
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Allarity Therapeutics presented two posters at the AACR 2026 Annual Meeting highlighting new data on stenoparib's potential in colorectal cancer and its Drug Response Predictor (DRP®) companion diagnostic's association with enhanced overall survival in ovarian cancer patients.
Key Facts
- Presented two posters at AACR 2026 Annual Meeting
- Poster 1 shows stenoparib DRP® scores associated with enhanced overall survival in ovarian cancer patients
- Poster 2 demonstrates stenoparib's unique mechanism of action in modulating the WNT/β-catenin signaling pathway and inhibiting colorectal cancer cell growth
- Stenoparib is a dual PARP and tankyrase inhibitor in Phase 2 clinical trials
Financial Impact
No direct financial impact disclosed; potential long-term value from clinical data supporting drug development
revenuecashFlow
Risk Factors
- Clinical trial results may not be predictive of future outcomes
- Regulatory approval is uncertain and may require additional trials
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-046411 |
| Document: ea0287156-8k_allarity.htm | 0001213900-26-046411 |
| Document: 0001213900-26-046411-index-headers.html | 0001213900-26-046411 |
| Document: 0001213900-26-046411-index.html | 0001213900-26-046411 |
| Document: 0001213900-26-046411.txt | 0001213900-26-046411 |
20 reports for ALLR
50% Hit rate @ T+20 Went positive at some point 5 of 6 best @ T+60▲ +38.71%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $1.04 | awaiting T+20 | — | $0.9200 (−11.54%) |
Sep 29, 2026 28d ago | 8-K | $0.9651 $0.9200 | ▼ −4.67% | ▼ −5.39% | $0.9200 (−4.67%) |
Sep 28, 2026 29d ago | Press Release | $0.9684 $0.9151 | ▼ −5.50% | ▼ −5.47% | $0.9200 (−5.00%) |
Sep 16, 2026 5w ago | 8-K | $1.16 $0.8699 | ▼ −24.68% | ▼ −27.86% | $0.9200 (−20.35%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $0.8601 | ▼ −26.49% | ▼ −28.75% | $0.9200 (−21.37%) |
Sep 11, 2026 6w ago | Press Release | $1.22 $0.9900 | ▼ −18.85% | ▼ −20.72% | $0.9200 (−24.59%) |
Aug 14, 2026 10w ago | Press Release | $1.37 $1.17 | ▼ −14.60% | ▼ −12.61% | $0.9200 (−32.85%) |
Jul 1, 2026 16w ago | 8-K | $1.33 $1.16 | ▼ −12.78% | ▼ −10.60% | $0.9200 (−30.83%) |
Jun 22, 2026 18w ago | 8-K | $1.36 $1.19 | ▼ −12.50% | ▼ −12.35% | $0.9200 (−32.35%) |
Jun 18, 2026 18w ago | Press Release | $1.43 $1.17 | ▼ −18.18% | ▼ −18.71% | $0.9200 (−35.66%) |
Showing 10 of 20
US Market Status
Market Closed — Opens Wed (< 1m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers